6 Sep, 2022
GloveOn Protect Antimicrobial Gloves Are Proven With Virucidal Efficacy Against Human Coronavirus & Monkeypox Virus
The COVID-19 pandemic has caused the loss of millions of lives worldwide and caused additional billions of dollars being spent on healthcare costs.
GloveOn Protect Antimicrobial Gloves is proven with virucidal efficacy against Human Coronavirus (Strain 229E), ATCC VR-740.
Lab result shows that GloveOn Protect can kill up to 99.696% of Human Coronavirus (Strain 229E). The report is based on a test strain modified from ASTM D7907-14 Standard Test Methods for the determination of virucidal efficacy on the surface of GloveOn Protect Antimicrobial nitrile powder free medical examination gloves.
By referring to the published information online from Therapeutic Goods Administration, Australia & United States Environmental Protection Agency, surrogate viruses, such as Human Coronavirus (Strain 229E), can be used to justify a COVID-19 efficacy claim.
Test data has proven a significant reduction of viruses
| Virucidal Reduction Efficacy against Human Coronavirus, % | ||||
Contact time | 5 mins | 10 mins | 20 mins | 30 mins |
| RΤ | 99.259% | 99.043% | 99.696% | 99.637% |
RΤ, Reduction from Challenge Inoculum (CI), RΤ = (CI-TS) x 100%/CI
GloveOn Protect is now tested to have virucidal efficacy against Modified Vaccinia Virus (Monkeypox Virus).
Monkeypox is a disease of global public health importance as it affects not only countries in west and central Africa, but the rest of the world. Studies are currently underway to further understand the epidemiology, sources of infection and transmission patterns. Monkeypox virus is transmitted from one person to another by close contact with rashes, scabs, body fluids, respiratory droplets, and contaminated materials such as clothing, bedding, or towels.
The proportion of patients who have died has varied between 0 and 11% in documented cases and has been higher among young children. Anyone can get or pass on viruses.
GloveOn Protect Antimicrobial Gloves have been tested to have virucidal efficacy against Modified Vaccinia Virus, Strain Ankara, ATCC VR-1508.
Lab result shows that GloveOn Protect can kill up to 99.000% of Modified Vaccinia Virus. The report is based on a test strain modified from ASTM D7907-14 Standard Test Methods for the determination of virucidal efficacy on the surface of GloveOn Protect Antimicrobial nitrile powder free medical examination gloves.
By referring to the published information online from Therapeutic Goods Administration, Australia, surrogate viruses, such as Vaccinia virus, can be used to justify a Monkeypox efficacy claim.
Test data has tested a significant reduction of viruses
| Virucidal Reduction Efficacy against Modified Vaccinia Virus, % | ||||
Contact time | 5 mins | 10 mins | 20 mins | 30 mins |
| RT | 91.459% | 93.387% | 96.135% | 99.000% |
RΤ, Reduction from Challenge Inoculum (CI), RΤ = (CI-TS) x 100%/CI
GloveOn Protect Antimicrobial Gloves does more than protect the glove users. With the ability to kill microbes, COVID-19 Virus and Monkeypox Virus, they also help in preventing the spread of viruses.
Choose GloveOn Protect Antimicrobial Gloves
for maximum protection.
